<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466867</url>
  </required_header>
  <id_info>
    <org_study_id>MUS90200_4025_1</org_study_id>
    <nct_id>NCT02466867</nct_id>
  </id_info>
  <brief_title>An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis</brief_title>
  <official_title>An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, multi-application pharmacokinetic study in pediatric
      subjects with tinea corporis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To quantify the plasma concentration of single and multiple dose of naftifine hydrochloride cream, 2% in pediatric subjects with tinea corporis</measure>
    <time_frame>2 weeks</time_frame>
    <description>AUC0-24, Cmax, AUC0-24/D, Cmax/D, AUCt,ss, Cmax,ss, AUCt,,ss/D, Cmax,ss/D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate plasma PK single and multiple dose PK variables</measure>
    <time_frame>2 weeks</time_frame>
    <description>tmax and tmax,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate trough plasma PK concentration</measure>
    <time_frame>2 weeks</time_frame>
    <description>Ctrough, ttrough,max, Ctrough,max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate urine PK single and multiple dose variables</measure>
    <time_frame>2 weeks</time_frame>
    <description>Ae0-24, fe, CLR, AEt,ss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Tinea Corporis</condition>
  <arm_group>
    <arm_group_label>Naftin® Cream, 2% (younger pediatric cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject aged 2 years to 5 years, 11 months with tinea corporis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftin® Cream, 2% (older pediatric cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject aged 6 years to 11 years, 11 months with tinea corporis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin® Cream, 2% (younger pediatric cohort)</intervention_name>
    <description>Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.</description>
    <arm_group_label>Naftin® Cream, 2% (younger pediatric cohort)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftin® Cream, 2% (older pediatric cohort)</intervention_name>
    <description>Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.</description>
    <arm_group_label>Naftin® Cream, 2% (older pediatric cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or females 2 to 11 years, 11 months of any race. Females of child producing age
             (started menarche) must have a negative urine pregnancy test.

          -  Presence of tinea corporis characterized by clinical evidence of a tinea infection at
             multiple sites covering a total of at least 1% body surface area.

          -  KOH positive and culture positive baseline skin scrapings obtained from the site most
             severely affected of the overall severity.

          -  Subjects must be in good health and free from clinically significant disease that
             might interfere with the study evaluations.

        Exclusion Criteria:

          -  Tinea infection of the scalp, face, groin, and/or feet.

          -  A life-threatening condition (ex. autoimmune deficiency syndrome, cancer) within the
             last 6 months

          -  Subject with abnormal findings-physically or laboratory- that considered by the
             investigator to be clinically important and indicative of conditions that might
             complicate interpretation of study results.

          -  Subjects with a known hypersensitivity or other contradictions to study medications or
             their components.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan B. Fleischer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merz North America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Merz Investigative Site#001261</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site#180001</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merz Investigative Site #504001</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <disposition_first_submitted>October 27, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 27, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 28, 2016</disposition_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ringworm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naftifine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

